{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T03:27:12Z","timestamp":1760239632310,"version":"build-2065373602"},"reference-count":42,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T00:00:00Z","timestamp":1606435200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Biogen Poland","award":["POL-TYS-13-10598"],"award-info":[{"award-number":["POL-TYS-13-10598"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Multiple sclerosis (MS) treatment with new agents is associated with the risk of the development of progressive multifocal leukoencephalopathy (PML). The seropositivity and a high index of anti-John Cunningham virus (JCV) antibodies are some of the risk factors for PML development. The aim of this study was to assess the seroprevalence of anti-JCVAb and JCVAb index (AI), as well as its correlations with demographic and clinical characteristics in treatment-na\u00efve Polish MS patients. This is a multicenter, prospective, and cross-sectional study involving 665 MS patients. The overall prevalence of anti-JCVAb was 65.3%, while 63.1% of seropositive patients had an index level of &gt;1.5. The seroprevalence was shown to increase along with the patient\u2019s age. Except for age, the prevalence of anti-JCVAb was not associated with demographic or clinical data. No correlations between the index levels and the demographic or clinical data were observed. In Poland, the seroprevalence of anti-JCVAb in treatment-na\u00efve MS patients is one of the highest in Europe. The majority of seropositive patients had an anti-JCV antibody level denoting a high-risk category. This means that we need further studies to be conducted on the individualization of MS treatment in order to provide patients with an appropriate therapeutic safety level.<\/jats:p>","DOI":"10.3390\/jcm9123867","type":"journal-article","created":{"date-parts":[[2020,11,28]],"date-time":"2020-11-28T03:51:16Z","timestamp":1606535476000},"page":"3867","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["JC Virus Seroprevalence and JCVAb Index in Polish Multiple Sclerosis Treatment-Na\u00efve Patients"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4077-8960","authenticated-orcid":false,"given":"Robert","family":"Bonek","sequence":"first","affiliation":[{"name":"Department of Neurology and Clinical Neuroimmunology, Regional Specialist Hospital, 86-300 Grudziadz, Poland"},{"name":"Foundation Supporting Development of Neurology and Clinical Neuroimmunology MoA, 85-654 Bydgoszcz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0183-2066","authenticated-orcid":false,"given":"Wojciech","family":"Guenter","sequence":"additional","affiliation":[{"name":"Department of Clinical Neuropsychology, Nicolaus Copernicus University, 87-100 Torun, Poland, and Collegium Medicum, 85-094 Bydgoszcz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Ja\u0142owi\u0144ski","sequence":"additional","affiliation":[{"name":"Department of Neurology, Regional Hospital, 71-455 Szczecin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Karbicka","sequence":"additional","affiliation":[{"name":"Department of Neurology, Regional Hospital, 71-455 Szczecin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Litwin","sequence":"additional","affiliation":[{"name":"Department of Neurology, Regional Hospital, 10-561 Olsztyn, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maciej","family":"Maciejowski","sequence":"additional","affiliation":[{"name":"KMK Clinical, MS Center, 40-571 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1654-8957","authenticated-orcid":false,"given":"Rados\u0142aw","family":"Zajdel","sequence":"additional","affiliation":[{"name":"Chair of Business Informatics, University of Lodz, 90-214 Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronique","family":"Petit","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical University of Lublin, 20-090 Lublin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7019-6681","authenticated-orcid":false,"given":"Konrad","family":"Rejdak","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical University of Lublin, 20-090 Lublin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,11,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"566-e41","DOI":"10.1111\/ene.13906","article-title":"The spectrum of progressive multifocal leukoencephalopathy: A practical approach","volume":"26","author":"Bartsch","year":"2019","journal-title":"Eur. J. Neurol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/ana.24371","article-title":"Persistence and pathogenesis of the neurotropic polyomavirus JC","volume":"77","author":"Wollebo","year":"2015","journal-title":"Ann. Neurol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/brain\/81.1.93","article-title":"progressive multifocal leuko-encephalopathy","volume":"81","author":"Mancall","year":"1958","journal-title":"Brain"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/S0140-6736(71)91777-6","article-title":"Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy","volume":"297","author":"Padgett","year":"1971","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1515\/hsz-2016-0345","article-title":"The biology of JC polyomavirus","volume":"398","author":"Assetta","year":"2017","journal-title":"Biol. Chem."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1212\/WNL.0b013e3181f73600","article-title":"Incidence of progressive multifocal leukoencephalopathy in patients without HIV","volume":"75","author":"Amend","year":"2010","journal-title":"Neurology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jbspin.2017.03.002","article-title":"Progressive multifocal leukoencephalopathy and rheumatoid arthritis treatments","volume":"84","author":"Moulignier","year":"2017","journal-title":"Jt. Bone Spine"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.ncl.2018.06.002","article-title":"Progressive Multifocal Leukoencephalopathy","volume":"36","author":"Grebenciucova","year":"2018","journal-title":"Neurol. Clin."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1474-4422(17)30282-X","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: A retrospective analysis of data from four clinical studies","volume":"16","author":"Ho","year":"2017","journal-title":"Lancet Neurol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ana.22128","article-title":"Anti-JC virus antibodies: Implications for PML Risk Stratification","volume":"68","author":"Gorelik","year":"2010","journal-title":"Ann. Neurol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1177\/1352458513477925","article-title":"Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort","volume":"19","author":"Olsson","year":"2013","journal-title":"Mult. Scler. J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/ana.24286","article-title":"Anti\u2013JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"76","author":"Plavina","year":"2014","journal-title":"Ann. Neurol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4578","DOI":"10.1212\/WNL.94.15_supplement.4875","article-title":"Progressive Multifocal Leukoencephalopathy in a Patient on Ocrelizumab Monotherapy","volume":"94","author":"Sul","year":"2020","journal-title":"Neurology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/ana.22606","article-title":"Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: Baseline results of STRATIFY-1","volume":"70","author":"Bozic","year":"2011","journal-title":"Ann. Neurol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1007\/s00415-012-6487-5","article-title":"Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy","volume":"259","author":"Outteryck","year":"2012","journal-title":"J. Neurol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1212\/WNL.0b013e3182583022","article-title":"Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort","volume":"78","author":"Trampe","year":"2012","journal-title":"Neurology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1136\/jnnp-2012-304332","article-title":"Changes to anti-JCV antibody levels in a Swedish national MS cohort","volume":"84","author":"Warnke","year":"2013","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1017\/cjn.2014.32","article-title":"Anti-JC Virus Antibody Prevalence in Canadian MS Patients","volume":"41","author":"Bhan","year":"2014","journal-title":"Can. J. Neurol. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/ene.12304","article-title":"Anti-JC virus (JCV) antibody prevalence in the JCV Epidemiology in MS (JEMS) trial","volume":"21","author":"Bozic","year":"2013","journal-title":"Eur. J. Neurol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jns.2013.11.031","article-title":"JCV epidemiology in MS (JEMS)\u2014Epidemiology of anti-JCV antibody prevalence in multiple sclerosis patients\u2014Portuguese data","volume":"337","author":"Santos","year":"2014","journal-title":"J. Neurol. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/ane.12475","article-title":"Anti-JC virus seroprevalence in a Finnish MS cohort","volume":"133","author":"Kolasa","year":"2016","journal-title":"Acta Neurol. Scand."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/eci.12721","article-title":"Study of the anti-JCV antibody levels in a Spanish multiple sclerosis cohort","volume":"47","author":"Rus","year":"2017","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann. Neurol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jcv.2013.02.002","article-title":"A second-generation ELISA (STRATIFY JCV DxSelect) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification","volume":"57","author":"Lee","year":"2013","journal-title":"J. Clin. Virol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1177\/1352458515599681","article-title":"Anti-JC virus antibody titres increase over time with natalizumab treatment","volume":"21","author":"Raffel","year":"2015","journal-title":"Mult. Scler. J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1007\/s00415-018-8996-3","article-title":"Anti-JC virus antibody index changes in rituximab-treated multiple sclerosis patients","volume":"265","author":"Baber","year":"2018","journal-title":"J. Neurol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"59","DOI":"10.25259\/SNI-4-2019","article-title":"Anti-John Cunningham virus antibody index levels in multiple sclerosis patients treated with rituximab, fingolimod, and dimethyl fumarate","volume":"10","author":"Farley","year":"2019","journal-title":"Surg. Neurol. Int."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3741260","DOI":"10.1155\/2019\/3741260","article-title":"Prevalence of Anti-JC Virus (JCV) Antibodies in the Multiple Sclerosis (MS) Population in Cyprus: A Retrospective Study","volume":"2019","author":"Lambrianides","year":"2019","journal-title":"Neurol. Res. Int."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jns.2016.03.050","article-title":"Anti-JC virus seroprevalence in a Spanish multiple sclerosis cohort","volume":"365","author":"Aladro","year":"2016","journal-title":"J. Neurol. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"116426","DOI":"10.1016\/j.jns.2019.116426","article-title":"JUSTIFY Investigators JC virus antibodies in Portuguese multiple sclerosis patients: JUSTIFY study results","volume":"406","author":"Nunes","year":"2019","journal-title":"J. Neurol. Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/ane.12699","article-title":"JCV serology in time: 3 years of follow-up","volume":"136","author":"Cambron","year":"2016","journal-title":"Acta Neurol. Scand."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e01332","DOI":"10.1002\/brb3.1332","article-title":"Conversion and reversion of anti-John Cunningham virus antibody serostatus: A prospective study","volume":"9","author":"Auer","year":"2019","journal-title":"Brain Behav."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.msard.2019.02.019","article-title":"The value of anti-JCV antibody index assessment in multiple sclerosis patients treated with natalizumab with respect to demographic, clinical and radiological findings","volume":"30","author":"Kolcava","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jns.2015.11.044","article-title":"JC virus seroprevalence and seroconversion in multiple sclerosis cohort: A Middle-Eastern study","volume":"360","author":"Alroughani","year":"2016","journal-title":"J. Neurol. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1007\/s13365-018-0646-0","article-title":"Anti-JC virus antibody sera positivity and index value among patients with multiple sclerosis may be correlated with age, sex, and area of residence","volume":"24","author":"Koolaji","year":"2018","journal-title":"J. NeuroVirol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1590\/0004-282x20180083","article-title":"Serological profile of John Cunningham virus (JCV) in patients with multiple sclerosis","volume":"76","author":"Branco","year":"2018","journal-title":"Arq. Neuro-Psiquiatr."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1007\/s00415-018-8813-z","article-title":"Serum anti-JCV antibody indexes in Japanese patients with multiple sclerosis: Elevations along with fingolimod treatment duration","volume":"265","author":"Aoyama","year":"2018","journal-title":"J. Neurol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3988\/jcn.2019.15.4.454","article-title":"High Seroprevalence and Index of Anti-John-Cunningham Virus Antibodies in Korean Patients with Multiple Sclerosis","volume":"15","author":"Kim","year":"2019","journal-title":"J. Clin. Neurol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Lau, A.Y.-L., Qiu, W., Kermode, A., Au, C., Ng, A., Wong, A., Ma, S.-H., Au, L., Ma, K., and Ip, B. (2018). High prevalence and indexes of anti-John Cunningham virus antibodies in a cohort of Chinese patients with multiple sclerosis. Mult. Scler. J. Exp. Transl. Clin., 4.","DOI":"10.1177\/2055217318788699"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e2077","DOI":"10.1002\/rmv.2077","article-title":"Progressive multifocal leukoencephalopathy and anti-CD20 monoclonal antibodies: What do we know after 20 years of rituximab","volume":"29","author":"Focosi","year":"2019","journal-title":"Rev. Med Virol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Hegen, H., Auer, M., Bsteh, G., Di Pauli, F., Plavina, T., Walde, J., Deisenhammer, F., and Berger, T. (2017). Stability and predictive value of anti-JCV antibody index in multiple sclerosis: A 6-year longitudinal study. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0174005"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e195","DOI":"10.1212\/NXI.0000000000000195","article-title":"Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values","volume":"3","author":"Schwab","year":"2016","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/12\/3867\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:38:42Z","timestamp":1760179122000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/12\/3867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,27]]},"references-count":42,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["jcm9123867"],"URL":"https:\/\/doi.org\/10.3390\/jcm9123867","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2020,11,27]]}}}